MedPath

A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Phase 3
Conditions
HIV Infections
Registration Number
NCT00006208
Lead Sponsor
Triangle Pharmaceuticals
Brief Summary

The purpose of this study is to compare the safety and effectiveness of emtricitabine and stavudine when given with didanosine plus efavirenz to HIV-infected patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (63)

Univ of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

East Bay AIDS Ctr

🇺🇸

Berkeley, California, United States

East Bay Clinical Trial Ctr

🇺🇸

Concord, California, United States

Mem Med Group Inc

🇺🇸

Long Beach, California, United States

AIDS Healthcare Foundation

🇺🇸

Los Angeles, California, United States

Orange Coast Med Group

🇺🇸

Newport Beach, California, United States

St Lukes Medical Group

🇺🇸

San Diego, California, United States

Robert Smith Medical Group

🇺🇸

San Diego, California, United States

Saint Francis Mem Hosp / HIV Care

🇺🇸

San Francisco, California, United States

Davies Med Ctr

🇺🇸

San Francisco, California, United States

Scroll for more (53 remaining)
Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.